NCT04094311 2026-04-20
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
Clinical Trials
14 trialsNCT06551324 2026-04-20
MEVPRO-1
Pfizer
Phase 3 Recruiting
NCT05888493 2026-04-17
LEDA
Novartis
Phase 3 Active not recruiting
NCT07062965 2026-04-16
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Phase 3 Recruiting
NCT03525873 2026-04-15
A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT06615479 2026-04-14
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Recruiting
NCT05455320 2026-04-13
MonumenTAL-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05572515 2026-04-13
MajesTEC-9
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT06149286 2026-04-13
OLYMPIA-5
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06064877 2026-04-09
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06713837 2026-04-08
IMPACT-AML
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 3 Recruiting
NCT06522737 2026-04-06
TERZO
SecuraBio
Phase 3 Recruiting
NCT05552976 2026-04-01
SUCCESSOR-2
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT07197580 2026-04-01
LUTEON
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting